Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ALB | P02768 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 2/20 | 0.52 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL7665465 | 1.00 | ALDH1A1 (0.65) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL16695889 | 0.96 | ALDH1A1 (0.70) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL13833316 | 0.96 | ALDH1A1 (0.70) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL19325461 | 0.96 | ALDH1A1 (0.70) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL8104283 | 0.96 | ALDH1A1 (0.70) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL3162 | 0.96 | ALDH1A1 (0.70) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| Triphosphate SCHEMBL6066340 | 0.93 | ALDH1A1 (0.59) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL18837721 | 0.88 | HPRT1 (0.52) | ALDH1A1LMNAALBMAPK1POLB | |
| SCHEMBL20758514 | 0.87 | POLB (0.59) | ALDH1A1LMNAALBMAPK1POLB | |
| SCHEMBL21417495 | 0.87 | POLB (0.59) | ALDH1A1LMNAALBMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0901531-B1 | PROCESS FOR DIRECT SEQUENCING DURING TEMPLATE AMPLIFICATION | SEQUENOM INC (US) | 2001-12-05 | — | — | EP | claimed |
| US-5928906-A | KIT CONTAINING CHAIN ELONGATING AND CHAIN TERMINATING NUCLEOTIDES AND TWO DIFFERENT POLYMERASES WHERE ONE POLYMERASE HAS HIGHER AFFINITY TOWARDS ONE CHAIN TERMINATING NUCLEOTIDE | SEQUENOM, INC. (US) | 1999-07-27 | — | — | US | claimed |
| EP-0901531-A1 | PROCESS FOR DIRECT SEQUENCING DURING TEMPLATE AMPLIFICATION | SEQUENOM, INC. (US) | 1999-03-17 | — | — | EP | claimed |
| WO-1997042348-A1 | PROCESS FOR DIRECT SEQUENCING DURING TEMPLATE AMPLIFICATION | SEQUENOM, INC. (US) | 1997-11-13 | — | — | WO | claimed |
| US-20240156764-A1 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| US-10725042-B2 | Methods of diagnosing and treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-07-28 | — | — | US | disclosed |
| US-10722530-B2 | Methods of diagnosing and treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190117663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIV CASE WESTERN RESERVE (US) | 2019-04-25 | — | — | US | disclosed |
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | disclosed |
| EP-2173333-B1 | COMBINATIONS OF ANTIFOLATE AGENT AND METHOXYAMINE IN THE TREATMENT OF CANCER | TRACON PHARMACEUTICALS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017176756-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2017-03-16 | — | — | US | disclosed |
| US-8017618-B2 | Administering antifolate anticancer agent and methoxyamine to enhance or increase the effect of the antifolate anticancer agent | TRACON PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100267657-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | CASE WESTERN RESERVE UNIVERSITY | 2010-10-21 | — | — | US | disclosed |
| EP-2173333-A2 | COMBINATIONS OF ANTIFOLATE AGENT AND METHOXYAMINE IN THE TREATMENT OF CANCER | Tracon Pharmaceuticals, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20080234298-A1 | ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | TRACON PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008083107-A2 | ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | TRACON (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20060241186-A1 | Alkylating agent combinations in the treatment of cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-26 | — | — | US | disclosed |
| WO-2003070234-A9 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003070234-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241186-A1 | Alkylating agent combinations in the treatment of cancer | UNG, TOP2A, OGG1 | ALDH1A1 2198/4885LMNA 2082/4885ALB 3388/4885 |
| US-20100267657-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | ALDH1A1 870/4885LMNA 2702/4885ALB 2208/4885 |
| US-10722530-B2 | Methods of diagnosing and treating cancer | UNG, TP53, OGG1 | ALDH1A1 372/4885LMNA 2490/4885ALB 2095/4885 |
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | UNG, TP53, OGG1 | ALDH1A1 372/4885LMNA 2490/4885ALB 2095/4885 |
| US-20080234298-A1 | ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | FEN1, UNG, FOLR1 | ALDH1A1 1686/4885LMNA 2146/4885ALB 1711/4885 |
| US-20190117663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PARP2, PARP1, PPP2CA | ALDH1A1 2368/4885LMNA 1383/4885ALB 3778/4885 |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | ALDH1A1 870/4885LMNA 2702/4885ALB 2208/4885 |
| US-20240156764-A1 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | UNG, OGG1, MPG | ALDH1A1 747/4885LMNA 315/4885ALB 2979/4885 |
| US-10725042-B2 | Methods of diagnosing and treating cancer | UNG, NTPCR, GUSB | ALDH1A1 156/4885LMNA 2476/4885ALB 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.